» Articles » PMID: 20683402

Stage-specific Embryonic Antigen 4 Expression in Epithelial Ovarian Carcinoma

Overview
Date 2010 Aug 5
PMID 20683402
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Stage-specific embryonic antigen 4 (SSEA-4) is a widely used marker to monitor the differentiation of pluripotent embryonic stem cells. Little is known about the expression pattern of SSEA-4 in solid tumors up to now.

Methods: In this study, we investigated the expression of SSEA-4 in 479 cases of various degrees of ovarian epithelial lesions by immunohistochemistry, consisting of 45 normal ovarian epithelia, 110 benign serous ovarian cystadenomas, 68 borderline serous ovarian cystadenomas, 104 invasive serous ovarian carcinomas, 64 benign serous mucinous cystadenomas, 48 borderline mucinous ovarian cystadenomas, and 40 invasive mucinous carcinomas. Moreover, the association between SSEA-4 expression and clinicopathological parameters was also evaluated.

Results: The expression of SSEA-4 was found to be increased from normal epithelium to benign cystadenoma and to borderline cystadenoma and adenocarcinoma in both serous and mucinous group. The loss or reduction of the expression of SSEA-4 was significantly correlated with more advanced tumor stage and poorer tumor cell differentiation.

Conclusions: We therefore proposed that SSEA-4 may play a role during the oncogenesis of epithelial ovarian carcinoma and posses a tumor suppressor effect during malignancy promotion. It could be a potential therapy target in patients with epithelial ovarian carcinoma.

Citing Articles

Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.

Chen N, Lin C, Lai T, Wu C, Liao P, Hsu T Proc Natl Acad Sci U S A. 2024; 121(5):e2313397121.

PMID: 38252815 PMC: 10835044. DOI: 10.1073/pnas.2313397121.


Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.

Pfeifer R, Al Rawashdeh W, Brauner J, Martinez-Osuna M, Lock D, Herbel C Int J Mol Sci. 2023; 24(11).

PMID: 37298141 PMC: 10252441. DOI: 10.3390/ijms24119184.


An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4.

Varier L, Sundaram S, Gamit N, Warrier S Cancers (Basel). 2023; 15(4).

PMID: 36831617 PMC: 9954718. DOI: 10.3390/cancers15041275.


Deciphering the Importance of Glycosphingolipids on Cellular and Molecular Mechanisms Associated with Epithelial-to-Mesenchymal Transition in Cancer.

Cumin C, Huang Y, Everest-Dass A, Jacob F Biomolecules. 2021; 11(1).

PMID: 33418847 PMC: 7824851. DOI: 10.3390/biom11010062.


Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.

Chen H, Liu J, Wang H, Cheng Q, Zhou C, Chen X J Cancer. 2019; 10(6):1580-1592.

PMID: 31031868 PMC: 6485236. DOI: 10.7150/jca.27352.